Tedros Adhanom Ghebreyesus & Mapp Biopharmaceutical

Tedros Adhanom Ghebreyesus: Tedros Adhanom Ghebreyesus, the Director-General of the World Health Organization, announced the launch of the trial and provided updates on the Ebola outbreak, highlighting the urgency and hope associated with the study.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.

Tedros Adhanom Ghebreyesus: Dr. Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, declared the Bundibugyo ebolavirus outbreak a Public Health Emergency of International Concern and welcomed the development of the new diagnostic test, emphasizing its importance in strengthening outbreak control.

Mapp Biopharmaceutical: Mapp Biopharmaceutical's experimental MBP134 antibody is being evaluated in a treatment trial for the Bundibugyo Ebola outbreak in the Democratic Republic of the Congo, either as a standalone treatment or in combination with Gilead Sciences' remdesivir.